The SURPASS-4 trial is the first randomized controlled trial assessing cardiovascular outcomes with Tirzepatide [45]
His commitment to justice and his clients' well-being is at the core of Vasquez Law Firm's mission
Women of childbearing age using tirzepatide should be advised to switch to a non-oral contraceptive method or add a barrier method." Specialist Pharmacy Service (SPS) For patients on tirzepatide, healthcare providers recommend switching to non-oral contraceptives or adding a barrier method (like condoms) for four weeks after starting the drug and four weeks after each dose increase
More specifically, we used the following treatment options: (1) metformin monotherapy, (2) injectable monotherapy, (3) one non-metformin oral agent, (4) metformin and one other oral agent, (5) injectable and metformin, (6) injectable and one non-metformin agent, (7) two non-metformin oral agents, (8) metformin and two other oral agents, (9) injectable and metformin and one other agent, (10) injectable and two non-metformin agents, (11) three non-metformin oral agents or at least four agents
Data from already published studies is presented in this review
.jpg)
